SHARESIFT
In short: Vertex Pharmaceuticals Incorporated (VRTX), a Healthcare company, scores 35/100 on ShareSift's value score and 5/9 on the Piotroski F-Score, with an Altman Z-Score in the safe zone as of 7 October 2026.
Healthcare · data ~15-min delayed
509.08 USD +1.35%
Open full interactive analysis →| Price | 509.08 USD |
| Day change | +1.35% |
| Market cap | 129.03B |
| 52-week range | 402.58 – 560.25 |
| P/E (trailing) | 29.6 |
| Dividend yield | 0.00% |
| Payout ratio | 0.00% |
| Return on equity | 23.54% |
| Debt / equity | 10% |
| Beta | 0.28 |
| Sector | Healthcare |
| Value score | 35 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Vertex Pharmaceuticals Incorporated (VRTX) scores 35/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 29.6 times trailing earnings and is classified in Healthcare. It does not currently pay a dividend. Return on equity is 24%, with debt at 10% of equity. On its filings it passes 5 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 5 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 14.56 — Safe zone.
Vertex Pharmaceuticals Incorporated (VRTX) scores 35/100 on ShareSift's value score as of 7 October 2026. The score is thirteen published pass/fail tests on reported figures: sixty points for valuation measures such as P/E and price-to-book, and forty for profitability, financial health, growth and dividends. A missing figure counts as a fail.
Vertex Pharmaceuticals Incorporated trades at 29.6 times its trailing twelve-month earnings as of 7 October 2026. The price-to-earnings ratio is the share price divided by earnings per share; a lower figure means paying less for each dollar of profit, though growth companies usually carry higher ratios.
Vertex Pharmaceuticals Incorporated does not currently pay a dividend as of 7 October 2026. Companies that retain all their earnings usually reinvest them in the business or use them to repay debt or buy back shares. Its dividend yield is therefore zero, and its returns to shareholders come from changes in the share price.
Vertex Pharmaceuticals Incorporated passes 5 of the nine Piotroski checks, which ShareSift reads as mixed. The F-Score compares the latest financial year with the one before on profitability, debt and liquidity, and operating efficiency. It shows the direction of the business, not whether the shares are cheap.
Vertex Pharmaceuticals Incorporated's Altman Z-Score is 14.56, in the safe zone. The score combines five balance-sheet and earnings ratios to gauge financial-distress risk: above 2.99 is safe, 1.81 to 2.99 grey, and below 1.81 distress. It was built for manufacturers and suits banks poorly.
Prices and fundamentals: Yahoo Finance (unofficial), as of 7 October 2026; prices are delayed about 15 minutes. Piotroski F-Score and Altman Z-Score: SEC EDGAR company filings, comparing the latest two annual reports. How each score is calculated: value score, F-Score, Z-Score. Every source ShareSift uses: data sources.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.